Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We serve patients with all types of cancer, who come from throughout the Mountain West, including Utah and parts of Idaho, Montana, Nevada, and Wyoming.
Our doctors and scientists include world-renowned experts dedicated to the highest quality standards and driven by the commitment to improve the lives of people affected by cancer.

Connect with us:

Latest from Huntsman Cancer Institute at the University of Utah

Orteronel Plus ADT Misses OS End Point in Metastatic Hormone-Sensitive Prostate Cancer

May 20, 2022

Article

The addition of orteronel to androgen deprivation therapy vs bicalutamide improved progression-free survival and prostate-specific antigen response in patients with metastatic hormone-sensitive prostate cancer, but missed the primary end point of overall survival in the phase 2 SWOG-1216 trial.

Dr. Osman on the SELECT-MDS Trial in Higher-Risk Myelodysplastic Syndrome

May 12, 2022

Video

Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.

Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer

May 01, 2022

Article

Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.

Dr. DeCesaris on Classical vs Contemporary Indications for Radiation in Breast Cancer

April 26, 2022

Video

Cristina DeCesaris, MD, discusses classical indications for breast cancer radiation and how these methods are being contextualized in the contemporary treatment era.

Institutional Perspectives in Cancer- Breast: Chaired by Christos Vaklavas, MD

March 15, 2022

Video

Multiple Myeloma Landscape Grows At Rapid Pace With Quadruplets and BCMA-Directed Therapy

February 10, 2022

Article

Douglas W. Sborov, MD, MS, discusses key data and therapeutic developments that have reshaped the treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

Institutional Perspectives in Cancer- Multiple Myeloma: Chaired by Douglas Sborov, MD, MS

December 15, 2021

Video

The Evolving Role of Prognostic Markers for CLL in the Era of Novel Agents

December 03, 2021

Article

Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.

Dr. Stephens on Early Intervention With Targeted Agents in CLL

November 15, 2021

Video

Deborah M. Stephens, DO, discusses early intervention with targeted agents to improve outcomes in patients with high-risk chronic lymphocytic leukemia.

Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

November 12, 2021

Video

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Soares on the Standard of Care in Metastatic Pancreatic Cancer

November 11, 2021

Video

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Dr. Soares on Advances in the Management of Pancreatic NETs

October 19, 2021

Video

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.

Atezolizumab/Cabozantinib Displays Promise in High-Risk mCRPC

October 12, 2021

Article

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.

Dr. Sborov on Supportive Care Approaches to Selinexor-Associated Toxicities in Multiple Myeloma

October 07, 2021

Video

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Dr. Agarwal on Adverse Effects With Belzutifan and Mitigation Strategies in RCC

October 06, 2021

Video

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

New Sequencing Strategies Could Hold Key to Improved Outcomes Across GI Malignancies

October 03, 2021

Article

Heloisa P. Soares, MD, PhD, discusses recent developments in NETS, pancreatic cancer, and GEJ tumors, as well as sequencing strategies aimed at improving patient outcomes across GI cancers.

Dr. Sborov on Managing Bispecific Antibody–Related Adverse Effects in Multiple Myeloma

September 29, 2021

Video

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Dr. Sborov on Mitigating Monoclonal Antibody–Associated Toxicities in Multiple Myeloma

September 23, 2021

Video

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Dr. Sborov on the Toxicities Associated With Novel Therapies in Multiple Myeloma

September 13, 2021

Video

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

Gastrointestinal Malignancies: Heloisa P. Soares, MD, PhD

September 09, 2021

Video